European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Protein Ruler to Create Affordable Biosensor Diagnosis for the Many

Cel

Ovarian cancer is the most common malignancy of the female reproductive system worldwide, and the leading cause of death from
gynecological cancer. However, if diagnosed during the early stages, patients have a good prognosis, at around 90% 5-year survival
rate. Despite its lethality, there are currently no effective simple tests for diagnosis nor population-based screening techniques for
ovarian cancer. Emerging tests detecting cancer biomarkers have the potential for greatest impact for surveillance and early
detection, such as the FDA approved CA125 and HE4 biomarkers. Importantly, because the levels of these biomarkers are not the
same among all healthy females and increase with age, these tests should be quantitative. Current quantitative diagnostic tests for
CA125 and HE4 detection are expensive, require high-cost infrastructures and trained professionals. Therefore, there is an urgent
need for developing cheap, reliable, easy-to-use quantitative tests for ovarian cancer biomarkers. In this project, ground-breaking innovating research will give rise to novel technology, enabling the detection of cancer biomarkers in a manner that is quantitative, and yet
simple, portable and cheap.

Słowa kluczowe

Instytucja przyjmująca

LUNDS UNIVERSITET
Wkład UE netto
€ 150 000,00
Adres
Paradisgatan 5c
22100 Lund
Szwecja

Zobacz na mapie

Region
Södra Sverige Sydsverige Skåne län
Rodzaj działalności
Higher or Secondary Education Establishments
Linki
Koszt całkowity
Brak danych

Beneficjenci (1)